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Pepsin and the Esophagus
Basil 1. Hirschowitza
Division of Gastroenterology and Hepatology, University ofAlabama at Birmingham,
Birmingham, Alabama
Esophagitis resultsfrom excessive exposure ofthe esophagus to gastricjuice through an ineffective
or dysfunctional lower esophageal sphincter mechanism. Apossible role ofpepsin in damaging the
esophageal mucosa with consequent esophagitis may be e,xamined directly by testingpepsin under
various conditions in experimental models ofesophagitis. Sincegastricjuice contains both acidand
pepsin, all experiments examine separately effects ofperfusion ofthe esophagus by acidwithoutand
withpepsin in various combinations. Acidperfusion alone at concentrations represented bypH 1.3
or above does notproduce esophagitis. The addition ofpepsin to acid between pH I and 3.5 caus-
es considerable acute esophageal damage. Outside theproteolytic range, i.e., higher thanpH 3.5,
pepsin does not damage the esophagus. The damage caused by acidifiedpepsin may be made much
worse by thefurther addition ofaspirin or other NSAIDs, presumably byfurther breaking down
mucosal barriers.
INTRODUCTION
The esophagus maintains its integrity
through many different mechanisms
(Figure 1). The focus of this discussion,
pepsin, looks at only part ofthe puzzle. A
role for pepsin in the causation of
esophagitis may be examined in several
ways. Experimental evidence shows an
important role for pepsin in acid medium
in the causation of acute damage to per-
fused rabbit or cat esophagus [1-3].
Whether and how this may be translated to
the chronic esophagitis seen clinically is
not clear. Measurement of pepsin concen-
tration and output in simple or complicat-
ed esophagitis (i.e., stricture, Barrett's) or
in esophagitis resistant to treatment has
failed to show a difference from appropri-
ate controls [4-7]. Furthermore, whether
pepsin plays a part in delaying or prevent-
ing healing ofclinical esophagitis is anoth-
erquestion ofgreat interest in designing or
interpreting the results oftreatment ofero-
sive esophagitis.
INTEGRITY AND DEFENSE OFTHE
ESOPHAGEAL MUCOSA
Esophagitis results from an abnormal
exposure to activated pepsin containing
acid gastric contents due to a distortion of
the physiological function of the LES [8].
Normal acid gastric contents refluxing into
the esophagus are rapidly and efficiently
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Figure 1. Model of the various mechanisms involved in the defense of the
esophageal mucosa. (Adapted from Brown and Rees. Gut 1996).
cleared through a combination of reflex
responses: propulsive orderly motility is
initiated to empty the esophagus of the
bolus, the esophagus secretes neutralizing
HCO3- and an esophago-salivary reflex
likewise initiates the flow of HCO3-rich
saliva. It is not clear whether these reflex-
es are operative during sleep, when sali-
vary flow ceases. Nocturnal acid reflux is
presumably more damaging because of
the loss of salivary neutralization.
Moreover, the esophageal squamous
mucosa represents a tight epithelium that
resists penetration by H+ [9, 10] and prob-
ably, in part, under the influence of epi-
dermal growth factor secreted by the sali-
vary glands, desquamated epithelium is
replaced, and damaged epithelium
repaired.
If this continuously balanced mecha-
nism is disrupted by one or more changes
in the elements of the equation, esophagi-
tis results; esophagitis, in turn, may have
secondary consequences. It is not known
whether there is more than one initiating
event, though it is clear that acid and
pepsin are the major sustaining factors in
esophagitis. However, not all reflux, much
ofwhich is physiological orvery transient,
results in esophagitis or even produces
symptoms [1, 8]. The threshold for these
consequences has not been defined.
There are a number of circumstances
in which an excess ofacid/peptic contents
reflux into the esophagus. First, an excess
of gastric contents may result from
delayed gastric emptying, which may be
physiological due to a large fatty meal, or
pathological as in pyloric stenosis or in
diabetic enteroneuropathy or other gastro-
paresis; the massive hypersecretion of
Zollinger-Ellison syndrome may also pro-
mote reflux, which is more damaging
because the refluxate is excessively acidic.
Obesity, ascites, and pregnancy promote
reflux because of increased abdominal
pressure, the latter also reducing LES
pressure by altered hormonal status. A lowHirschowitz: Pepsin and the esophagus 135
LES pressure is normally present in
infants.
In some adults, the LES may be
intrinsically weak (< 10 mm Hg), and in
most such cases, esophagitis results [4].
However, this defect accounts for no more
than 30 percent ofcases ofesophagitis [4].
The LES may be rendered incompetent by
an axial hiatal hernia, which often addi-
tionally functions as an intrathoracic reser-
voir of gastric contents at the thoracic
pressure, so that the esophagus is not fully
cleared of acid. Hiatal hernia is present in
only half the cases of esophagitis. The
LES can also be damaged by operations,
such as a myotomy for achalasia. The rea-
son why an LES with normal pressure
relaxes inappropriately is unknown. This
functional defect accounts for many ofthe
remaining cases ofreflux.
There are no good data in man, as
opposed to experimental models, defining
the conditions necessary to induce
esophagitis. We do not know the necessary
duration of exposure, the minimum com-
position of the refluxate, nor whether the
esophagus is more vulnerable at any par-
ticular time of day or night. In experimen-
tal models, acid without pepsin is much
less ulcerogenic, and it may be assumed
thatpepsin is as important in the genesis of
esophagitis [11] as it is in its continuance.
This hypothesis is strongly supported by
the efficacy ofomeprazole.
EXPERIMENTAL ESOPHAGITIS
To delineate a possible role of pepsin
we first examine experimental studies. It
has been shown in several studies that acid
perfusion alone of the esophagus or
jejunum will not produce damage, where-
as perfusion with added pepsin, or whole
gastric juice will [3]. Figure 2 shows that
acute esophageal damage does not occur
with acid alone at pH 1.3 (approximately
50 meq/l) or above [3]. An esophageal
mucosal barrier to hydrogen has been
described in dogs, rabbits, and humans [9,
10]. This is a functional concept defined




mEq/l pH 0 25 50 100 200
5 2.3 0
10 2.0 0 .3 1.3
HCI 25 1.6 .2 1.6 2.7 2.0 2.1
50 1.3 1.8 2.7 4
100 1.0 4 3 3.3
Figure 2. Damage levels to rabbit esophagus perfused for 1 hour by various combi-
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Figure 3. Proteolytic activity of pepsin and of gastric juice at various levels of pH
[from Ref. 34].
to prevent the back-diffusion of hydrogen
from the lumen and involves different
mechanisms, including the hydrophilic
lipid bilayers ofcell membranes, the inter-
cellular barriers orjunctional complex, the
intracellular buffer capacity for hydrogen
ions, and the ability of cells to extrude
hydrogen ions into the interstitial fluid
(sodium-hydrogen antiport) [9].
However, the addition of pepsin at
concentrations commonly found in human
gastric juice leads to significant damage.
At pH values of more than 3, the effect of
pepsin is much diminished (Figure 3).
However, gastric juice also contains other
proteases, such as cathepsins B and D,
which extend the proteolytic optimum to
pH 4 (Figure 3). In another situation,
injury ofthe gastric mucosa in experimen-
tal hemorrhagic shock can beprevented by
a pepsin-binding analog of pepstatin [12,
13] suggesting an important role for
pepsin in this process. The pepstatin
experiments [12] suggest a role for intra-
mucosal-activated pepsin, but itremains to
be shown whether the pH in the mucosa
reaches the range of less than pH 3.3
required for pepsin action. Even if it did,
such a degree ofacidity would by itselfbe
highly disruptive. "Normal" reflux may in
fact be protective, as suggested by adapta-
tion ofesophageal mucosa exposed briefly
to acid in developing resistance to subse-
quent acid/pepsin injury . This adaptation
is not dependent on cell proliferation and
may be mediated by NO and EGF [2].
Pepsin activity is dependent on acid.
At pH 6.0 orbelow, pepsinogen is autocat-
alytically converted to pepsin which is
optimally active at pH 1-3.3 (Figure 3).
Pepsin is denatured at apH ofmore than 7
and therefore remains present and activat-
able at pH 3.5 to 6.9 [11]. Since most
agents directed to ulcer treatment do not
elevate gastric pH > 7.0, pepsin is not
destroyed.
If pepsin were to penetrate below the
surface epithelium, a possible target of
proteolysis would be collagen, especially
type IV which is hydrolyzed by pepsin atHirschowitz: Pepsin and the esophagus 137
the non-helical ends of the molecules
releasing monomers [14]. This would dis-
rupt mucosae since cross-linking of colla-
gen by carbohydrate moieties occur at the
non-helical spacings [15]. Collagen IV
makes up the basement membrane for sur-
face epithelial as well as endothelial cells
[16] and its disruption could quite readily
be seen as leading to esophagitis and sim-
ilar diffuse mucosal lesions. Once the sur-
face epithelium is partly disrupted, the
process then would allow further access of
damaging acidified proteases (Figure 4).
Another possible pathogenic role for
pepsin via digestion of collagen might
occur during the repair of chronic ulcera-
tion. Since new collagen is essential to the
structural repair of the mucosa, including
new blood vessels [16] the high suscepti-
bility ofboth collagen III and IV to peptic
digestion [14, 15] might delay ulcer heal-
ing. Since the repair of esophagitis is
much more rapid with more profound sup-
pression ofacid by omeprazole, i.e., when
pepsin is rendered inactive, themechanism
that promotes healing might involve
removal of proteolysis rather than pH per
se. Therefore, greater acid suppression is
necessary to ensure healing ofesophagitis.
No reliable non-toxic potent pepsin antag-
onist is available to test these possibilities
independently of acid in vivo.
ROLE OF OTHER AGENTS
Injury in experimental esophagitis is
promoted by other agents that damage the
epithelium and so render it more perme-
able to acid and pepsin, thus causing
mucosal disruption and esophagitis
(Figure 4). Among the agents that may do
so are aspirin [1] or similar compounds
[17-20]. The clinical evidence for a con-
tributory role ofaspirin are the presence of
esophagitis in 16 to 20 percent of healthy
volunteers taking NSAIDs [17-18], and 25
percent incidence of esophagitis among
patients taking NSAIDs compared to 15
percent in controls [19]. We [20] recently
reported an unexpectedly high proportion
(61 percent) of esophagitis patients taking
NSAIDs chronically, mostly aspirin. Also
esophagitis is a common feature among
patients with refractory peptic ulcer due to
ASA abuse [21].
Other agents that may cause primary
damage to the esophageal epithelium
include bile and locally acting medications
S
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Figure 4. Schematic representation of esophageal mucosa showing possible mech-
anisms involving pepsin in causing or promoting esophagitis through proteolytic
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Figure 5. Basal and maximally stimulated pepsin and acid output in patients with
esophagitis and in appropriate controls with the same background upper GI disease.
ZES = Zollinger-Ellison syndrome; HYS = duodenal ulcer hypersecretors BAO > 15
mEq/hr; DU = duodenal ulcer, non-DU, and surg = patients after gastric surgery for peptic
ulcer. Numbers below each column represent number of patients and controls, respective-
ly [data from Ref. 4 with permission].
in pill form such as quinidine, especially
in the formulation Quinaglute, tetracy-
cline, ferrous sulfate and KCI, especially
with underlying motility disorders leading
to poor clearance.
Experimental data thus suggest an
important primary as well as secondary
role for pepsin in causing or promoting
acute esophagitis.
CLINICAL ESOPHAGITIS
There is no direct evidence for a
definitive role for pepsin in causing clini-
cal esophagitis. Since there is no specific
clinically useful antagonist to pepsin,
direct proof of contribution of pepsin to
persistence of esophagitis in man is lack-
ing. Measurement of acid reflux (e.g., by
pH probe and using pH 4.0 as threshold) is
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Figure 6 (left). Basal and pentagastrin stimulated acid and pepsin secretion in
patients with Barrett's esophagus and in age, race and sex-matched controls with
esophagitis. [From Ref. 6 with permission]. Figure 7 (right). Basal and pentagastrin
stimulated acid and pepsin secretion in patients with esophageal stricture and age
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exposure. For pepsin exposure alone, the
pH threshold would be approximately 3.3
(Figure 3). A rough estimate ofnon-pepsin
contribution proteolytic activity may be
obtained from the interval between pH 3.3
and 4.2. Moreover, since acid per se at pH
of more than 2.5 causes no damage to the
esophagus [3], it may be inferred that
exposure between 2.5 and 4 is damaging
solely by proteolysis. Most reports of 24-
hr pH shows that longer exposure to pH of
less than 4 is associated with increasingly
severe esophagitis [8]. We, therefore, fur-
ther examined the question by measuring
acid and pepsin in gastric juice (the sole
source of acid and pepsin in the refluxate)
in esophagitis, both simple and complicat-
ed, to learn whether the composition ofthe
refluxate was a factor added to exposure
time. Because esophagitis is found in
patients with widely different secretory
backgrounds from Zollinger-Ellison gas-
tric hypersecretors at the one extreme to
post-gastric surgery patients with low acid
and pepsin secretion at the other, it was
important to use appropriate controls [4].
Basal and maximal acid and pepsin out-
puts were higher in males than females
[4], but the same or slightly lower than
controls and patients with esophagitis
(Figure 5). Moreover, composition of gas-
tric juice - pH and acid and pepsin con-
centrations - was no different in fasting
gastric, juice in each subgroup between
esophagitis patients and controls.
However, patients with very low secretion
(BAO < 0.1 meq/hr) rarely had esophagitis
[4]. With acid (and pepsin) secretion pre-
sent however, severity of esophagitis was
unrelated to levels ofacid output [4].
100% -
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Figure 8. 24-hr intragastric pH values in 10 volunteers with three different acid sup-
pressing drugs: cimetidine, ranitidine and omeprazole, respectively. Superimposed
on each is the activity curve for pepsin, the optimum activity at pH 1.2 to 30. [From Ref. 24
with permission].Hirschowitz: Pepsin and the esophagus 141
On further examining patients with
treatment-resistant [5] or complicated
esophagitis stricture [6] or Barrett's [7],
and using patients with esophagitis who
healed, or patients with esophagitis with-
out stricture or Barrett's as appropriate age
and sex-matched controls, there was no
difference between patients andcontrols in
basal or maximally stimulated acid or
pepsin output, or concentrations of acid
and pepsin in fasting gastric contents.
Figures 6 and 7 illustrate the almost iden-
tical acid and pepsin outputs in thepatients
in the stricture and Barrett's studies.
The data derived from studying gas-
tric secretion offer no direct evidence for a
definitive role of altered pepsin secretion
in esophagitis or its complications, show-
ing only that in the virtual absence of acid
(and pepsin), esophagitis rarely occurred.
EVIDENCE FROMTHERAPY OF
ESOPHAGITIS
Unlike the healing of peptic ulcer
[22], healing of esophagitis requires more
profound and prolonged 24-hr acid sup-
pression [23]. Such suppression of acid
secretion cannot be generally obtained
with conventional "ulcer healing" doses of
H2 antagonists, and thus healing of
esophagitis, especially grade II or greater,
requires the more profound acid inhibition
achievable only with proton pump
inhibitors [25-28], and in adequate doses
[29]. Moreover, maintenance ofthe healed
state also requires daily treatment with
proton pump inhibitor [29-31].
The principal difference between H2
antagonists and proton pump inhibitors on
gastric secretion is found in the degree to
which pH is elevated. In normal volun-
teers, [32], the median pH for gastricjuice
over 24 hr was elevated to 1.8 by cimeti-
dine (1 gm daily), to pH 2.2 by ranitidine
(300 mg daily), but to pH 5.5 by omepra-
zole 30 mg per day, thus elevating pH out
of the activity range of pepsin (pH < 3.3,
Figure 8) or in fact of all acid proteases
found in gastric juice (Figure 2, Ref. 2)
(pH < 4.2). Where 24 pH shows inade-
quate acid suppression by proton pump
inhibitors esophagitis relapses [33]. Short
of using a specific pepsin inhibitor, which
is not currently possible, one cannot dis-
tinguish between the effect of acid sup-
pression per se and the effect of acid sup-
pression by elevation of pH to outside the
range ofpeptic activity in promoting heal-
ing.
However, when combined with the
evidence of acute experimental esophagi-
tis models cited above, and the interpreta-
tion from Figure 8, there is enough cir-
cumstantial evidence to implicate acid
active proteases, especially pepsin as the
essential component in gastric refluxate
responsible for causing and perpetuating
the diffuse disorder oferosive esophagitis.
With persistence of the underlying
pathophysiology that allows abnormal
exposure ofthe esophagus to refluxed gas-
tricjuice, this conclusion leads to the clear
therapeutic implication that requires such
gastric contents to be above pH 4 in order
to heal esophagitis and to prevent relapse.
The proportion of the 24 hr necessary for
the esophagus to be exposed to this degree
ofsuppression appears to be in the orderof
75 percent (16 hr/day) or more [23].
Prevention ofexcessive reflux may achieve
the same goal, perhaps even without
changing pH as in successful anti-reflux
surgery. The problem of esophagitis is a
multifactorial one as shown in Figure 1.
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